• The phase 2 study enrols patients with advanced HPV16 positive oropharyngeal head and neck cancer that failed previous anti-PD1 treatment• The trial is part of a clinical development plan that is aimed at a Biological License Application (BLA) for this combination immunotherapy
Oegstgeest, The Netherlands, September 8, 2021 – ISA announces the start of patient dosing in a pivotal clinical trial investigating the combination of ISA101b and Libtayo® (cemiplimab) in advanced HPV16 positive oropharyngeal cancer. This new study is the third with active recruitment under ISA Pharmaceuticals’ strategic immuno-oncology collaboration with Regeneron.
The oropharyngeal cancer phase 2 study (NCT04398524) will include
Oegstgeest, The Netherlands, May 04, 2021 – ISA announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines. The paper is co-authored by ISA’s Chief Scientific Officer, Prof. Cornelis “Kees” Melief in collaboration with key opinion leaders at international institutions including the Icahn School of Medicine at Mount Sinai, New York, the Parker Institute of Cancer Immunotherapy, San Francisco, and the Leiden University Medical Center in The Netherlands. This is the link to the online article.
The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials. It provides an overview
Oegstgeest, May 3rd, 2021 – ISA is happy to announce it has moved into its new location in the Biopartner 5 building, situated in the western part of the Leiden/Oegstgeest BioScience park.
Our new address is:De Limes 72342 DH OegstgeestThe Netherlands
The novel ISA facilities constitute a doubling in size of office and lab space, compared to its former location, with possibilities to further expand. Over the past period ISA has grown substanially and will continue to do so in the coming period. This new location is perfectly suited to accommodate this growth.
The Biopartner 5 building is designed with emphasis on sustainability:
Leiden, The Netherlands, 01 July 2020 — ISA Pharmaceuticals B.V., today announced that it received Orphan Drug Designation from the Food and Drug Administration (FDA) in the USA for its lead product ISA101b for treatment of Human Papilloma Virus type 16 (HPV16)-positive cervical cancer.
According to the latest statistics of the Centers for Disease Control and Prevention, HPV causes more than 34,000 cases of cancer in the United States each year. Cervical cancer is the most common HPV-associated cancer in women, with HPV16 being responsible for approximately 50% of cases. HPV16-positive cervical cancer is the number 2 cause of cancer for women in
This article by Anna Scherer, posted on the Accelerating Cancer Immunotherapy Research (ACIR) website, very elegantly explains ISA’s CervISA study, which was published recently in Science Translational Medicine. Click here to access the ACIR article.
Blog by Arthur N. Brodsky, PhD, published on Cancerresearch.org on 27 March 2020. Click here to access the original article.
Just weeks after International Human Papilloma Virus (HPV) Awareness
Day, new results
from two long-time Cancer Research Institute (CRI) scientists highlighted the
promise of immunotherapy against HPV-associated cervical cancer.
In a phase 1/2 study, women with advanced, recurrent, or
metastatic cervical cancer were treated with the combination of an
HPV-targeting vaccine and standard-of-care chemotherapy. Of 72 evaluable
patients, 43 percent had their tumors shrink.
Led by Cornelis J.
M. Melief, M.D, Ph.D., and Sjoerd H. van der Burg, Ph.D.,
this clinical breakthrough was the latest fruit borne by the duo, both of
whom have been supported
The platform for the medical research community MedNous wrote an article about our CervISA study:
Synthetic long peptides deliver response
A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy.
Sunday 22 March 2020A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy. The Phase 2 trial showed that the vaccine and carboplatin/paclitaxel chemotherapy were associated with prolonged survival.
The study was led by Cornelis Melief, chief scientific officer of ISA Pharmaceuticals
Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including meaningful survival improvements in SLP immune responders
Leiden, The Netherlands, 19 March 2020 — ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, announces publication of its phase 2, CervISA study in the peer-reviewed journal “Science Translational Medicine”. The paper titled ‘Strong vaccine responses during chemotherapy are associated with prolonged survival’ can be found here.
The CervISA study was an open label, phase 2 study in patients with late stage HPV16 positive cervical cancer. Seventy-seven patients were treated with ISA Pharma’s lead product, ISA101b, an HPV16-specific immunotherapeutic